Announcements A Joint Statement on Technical, legal, ethical and implementation concerns regarding Aarogya Setu and other apps introduced during COVID-19 in India by Jan Swasthya Abhiyan (JSA), Internet Freedom Foundation (IFF), Forum for Medical Ethics Society (FMES), and All India People’s Science Network (AIPSN)   |   Submission to the National Human Rights Commission (NHRC) on behalf of Hub5 (HEaL Institute, APU, Seher-CHSJ, and IAPH) – COPASAH on human rights issues confronted by ASHAS and ANMs during the Covid-19 pandemic | Aug 7, 2020   |   Letter to MMC by FMES, PUCL-MH, FAOW, and MFC urging to restore its order suspending licenses of two doctors accused of abetting the suicide of Dr Payal Tadvi

Taking biotechnology to the patient: at what cost?

D Varatharajan


Abstract

Enlargement of people’s choices is one form of human development. To this extent, biotechnology as a treatment option for certain human ailments such as genetic disorders can be taken as an effort towards human development, as it definitely extends the range of choices available to the public. The issue of ‘taking biotechnology to the patient’ goes beyond mere technology development, which is a supply side activity that may not take into account the demand side requirements such as accessibility and affordability-two important attributes for the success of any intervention technique.

Full Text

HTML PDF

Keywords

N/A

Refbacks

There are currently no refbacks.

Article Views

PDF Downloads

Click here to support US